Thermo Fisher expands collaboration Multiply Labs for automated cell therapy manufacturing

Published: 1-Oct-2025

The strategic collaboration will aim to integrate robot automation with the Gibco CTS DynaCellect Magnetic Separation System for a more efficient manufacturing process

Multiply Labs has announced an expansion of its collaboration with Thermo Fisher Scientific.

The expanded collaboration will focus on integrating Thermo Fisher’s automated Gibco CTS DynaCellect Magnetic Separation System with Multiply Labs’ state-of-the-art robotic platforms. 

The Gibco CTS DynaCellect System is a closed, automated isolation, activation and bead removal system for cell therapy development and manufacturing.

Together with fit-for-purpose consumables, it offers high cell purity, recovery and viability.

The combination of Gibco CTS DynaCellect System with Multiply Labs’ robotic automation will accelerate critical steps in cell therapy production through the reduction of manual intervention and improved consistency in processes.

"Thermo Fisher is committed to advancing cell therapy manufacturing through innovative, scalable solutions,” said Andy Campbell, Senior Director of Research and Development at Thermo Fisher Scientific.

"Our expanded collaboration with Multiply Labs will enable customers to achieve end-to-end automation in their manufacturing processes, ultimately accelerating the delivery of transformative therapies to patients."

Multiply Labs’ robotic systems are designed to automate complex biomanufacturing workflows, enabling high-throughput, flexible production of cell therapies.

Integrating these capabilities with the Gibco CTS DynaCellect System will enhance customers' ability to achieve seamless, end-to-end cell separation and processing.

"We are excited about continuing to integrate leading, GMP-ready instruments with our robotic technology," said Fred Parietti, co-founder and CEO of Multiply Labs.

"This extended partnership is another step toward fully autonomous cell therapy manufacturing, reducing costs, minimising human error and ultimately getting treatments to patients faster."

The expanded partnership builds on the companies’ existing collaboration, which has focused on automating cell expansion and separation processes, including the Heracell VIOS Automated Access CO2 Incubator and the Gibco CTS Rotea Counterflow Centrifugation System.

You may also like